胆固醇与骨质疏松  

Cholesterol and osteoporosis

作　　者：张洁[1] 曹奇[1] 唐朝克[2] ZHANG Jie CAO Qi TANG Chao-Ke(Department of Spine Surgery, the Second Affiliated Hospital, University of South China, Hengyang, Hunan 421001, China Research Institute of Cardiovascular Disease ＆ Key Laboratory for Atherosclerology of Hunan Province ＆ Medical Research Center, Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, University of South China, Hengyang, Hunan 421001, China)

机构地区：[1]南华大学附属第二医院脊柱外科 [2]南华大学心血管疾病研究所动脉硬化学湖南省重点实验室医学研究中心湖南省分子靶标新药研究协同创新中心,湖南省衡阳市421001

出　　处：《中国动脉硬化杂志》2017年第4期422-426,共5页Chinese Journal of Arteriosclerosis

基　　金：国家自然科学基金资助项目(81570408)

摘　　要：流行病学研究表明骨质疏松症发病风险与心血管疾病发病率之间具有正相关,高胆固醇血症对骨质疏松症的发生起重要作用。血清胆固醇、低密度脂蛋白胆固醇水平升高可导致骨密度下降,促进骨质疏松症的发生。破骨细胞和成骨细胞是维持骨动态平衡主要的骨代谢细胞,而胆固醇对骨代谢细胞的功能有重要影响。本文主要综述胆固醇和他汀类降胆固醇药物对成骨细胞和破骨细胞分化、形成及活性的影响,旨在为骨质疏松症的防治提供新的思路。Epidemiological studies show that there is a positive correlation between the risk of osteoporosis and the incidence of cardiovascular disease, and hypercholesterolemia plays an important role in the occurrence of osteoporosis. The increase of serum cholesterol and low density lipoprotein cholesterol can lead to the decrease of bone mineral density and the occurrence of osteoporosis. Osteoclast and osteoblast are the main bone metabolisna cells to maintain bone homeostasis, and cholesterol plays an important role in bone metabolism. This review summarizes the effects of cholesterol and cholesterol-lowering drugs （statins） on the differentiation, formation and activity of osteoblast and osteoclast, thereby providing a novel strategy for the prevention and treatment of osteoporosis.

关 键 词：胆固醇 骨质疏松 骨密度 心血管疾病 

分 类 号：R363[医药卫生—病理学]